Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training
Condition(s) studied
Investigational drug(s) / intervention(s)
Nicotinamide Riboside (NR): 600 mg NR
Nicotinamide Riboside (NR): 300 mg NR
Study summary
Zone 2 training, a low-intensity endurance exercise performed at approximately 66-80% of VO₂max or near the first ventilatory threshold, has gained popularity for improving aerobic capacity, fat metabolism, and mitochondrial efficiency. It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers. Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis. It participates in oxidative reactions within the tricarboxylic acid cycle and electron transport chain, sustaining ATP synthesis and mitochondrial efficiency. Exercise influences multiple pathways of NAD metabolism, altering the NAD⁺/NADH ratio and thereby affecting energy production and fatigue resistance. Studies have shown that both aerobic exercise and NAD precursor supplementation (e.g., nicotinamide riboside \[NR\]) can elevate body NAD levels and enhance mitochondrial function, though findings remain inconsistent due to variations in dosage and participants' characteristics. This study aims to investigate how acute NR supplementation interacts with Zone 2 cycling training in adults. Specifically, it examines the temporal and dose-dependent effects of NR supplementation on metabolic flexibility and exercise performance. The results may clarify the potential synergistic benefits of combining NAD supplementation with low-intensity endurance training to improve aerobic adaptability.
Eligibility
Primary outcome measure(s)
- Substrate utilization (CHO and fat oxidation rate) — From enrollment to the end of treatment at 4 weeks
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| G02, Kwok Sports Building, The Chinese University of Hong Kong | Hong Kong | Please Select | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07344636 on ClinicalTrials.gov ↗ ← All trials in China